Apyx Medical financials
$2.60+4.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $52.8M | $48.1M | $52.3M | $44.5M | $48.5M | $27.7M | $28.2M |
| Gross profit | $33.0M | $29.4M | $33.8M | $29.1M | $33.6M | $17.5M | $19.1M |
| Gross margin | 62.5% | 61.0% | 64.5% | 65.4% | 69.3% | 63.2% | 67.6% |
| Operating income | -$6.4M | -$18.8M | -$20.0M | -$23.1M | -$14.8M | -$19.6M | -$21.2M |
| Net income | -$11.2M | -$23.5M | -$18.7M | -$23.2M | -$15.2M | -$11.9M | -$19.7M |
| Net margin | −21.2% | −48.8% | −35.7% | −52.1% | −31.3% | −42.9% | −69.8% |
| Diluted EPS | $-0.27 | $-0.66 | $-0.54 | $-0.67 | $-0.44 | $-0.35 | $-0.58 |
| EBITDA | -$5.8M | -$18.2M | -$19.3M | -$22.2M | -$13.9M | -$18.7M | -$20.5M |
| Operating cash flow | -$8.0M | -$18.0M | -$5.2M | -$20.3M | -$10.4M | -$16.1M | -$18.5M |
| Free cash flow | -$9.1M | -$18.8M | -$5.8M | -$21.3M | -$11.2M | -$16.6M | -$19.8M |
| Diluted shares | 41.1M | 35.5M | 34.6M | 34.5M | 34.3M | 34.2M | 34.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $31.7M | $31.7M | $43.7M | $10.2M | $30.9M | $41.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $34.9M | $33.9M | $33.3M | $110.0K | $183.0K | $421.0K |
| Total assets | $66.8M | $64.8M | $79.2M | $51.8M | $68.7M | $74.1M |
| Total liabilities | $52.0M | $50.5M | $52.3M | $14.0M | $14.7M | $10.3M |
| Shareholders' equity | $14.8M | $14.3M | $26.9M | $37.8M | $54.0M | $63.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology